A Phase 4 interventional study of Tranexamic Acid and Normal Saline in Knee Osteoarthritis, sponsored by The Second Affiliated Hospital of Kunming Medical University. Not yet recruiting at 1 site in China. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by The Second Affiliated Hospital of Kunming Medical University · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing Tranexamic Acid in Osteoarthritis, Knee — 2 open to participants now, 2 under way, 1 of them phase 3. Tranexamic Acid · Osteoarthritis, Knee.
Among the 15 studies testing Tranexamic Acid in Osteoarthritis, Knee, this one is the 12th largest by planned enrollment, is the only one that started in 2026, is one of 7 in phase 4, and was the 15th registered.
3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.
Browse Osteoarthritis, Knee studies →2 of the 15 studies testing Tranexamic Acid in Osteoarthritis, Knee are open now, in 1 country. Recruiting first, the newest first:
Western University, Canada
By country, each count listing its studies:
Tranexamic Acid: first FDA approval 1986 (CYKLOKAPRON). What it is approved for, and how studies give it, is on its page →
Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 50 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 70 is close to the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 100 across the 15 interventional studies. Of the 8 that completed or were terminated, 3 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 15 has an industry lead sponsor. The 10 most frequent:
The Second Affiliated Hospital of Kunming Medical University is the lead sponsor of 17 studies on the registry; 11 are open to participants now.
The Second Affiliated Hospital of Kunming Medical University has 1 study filed under Osteoarthritis, Knee — fewer than ten, so there is no comparison to draw.
1 of the studies testing Tranexamic Acid in Osteoarthritis, Knee that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07853885The Second Affiliated Hospital of Kunming Medical UniversityIntraosseous Tranexamic Acid for Reducing Blood Loss in Total Knee Arthroplasty | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies testing Tranexamic Acid in Osteoarthritis, Knee, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective, single-center, randomized, double-blind, placebo-controlled trial aims to evaluate the efficacy and safety of local intraosseous tranexamic acid administration for reducing perioperative blood loss in patients undergoing primary unilateral total knee arthroplasty (TKA). A total of 70 patients with primary knee osteoarthritis will be randomly assigned in a 1:1 ratio to either the tranexamic acid group or the placebo control group. Before skin incision, participants in the experimental group will receive local intraosseous tranexamic acid, while participants in the control group will receive an equal volume of normal saline using the same injection procedure. The primary outcome is total perioperative blood loss. Secondary outcomes include postoperative hemoglobin reduction, transfusion requirements, pain, knee swelling, range of motion, functional recovery, length of hospital stay, and postoperative complications. Participants will be followed for up to 3 months after surgery.
Total knee arthroplasty may be associated with substantial perioperative blood loss. Tranexamic acid is commonly used to reduce bleeding during joint arthroplasty, but conventional systemic administration may result in greater systemic drug exposure. Local intraosseous administration may provide a higher drug concentration at the surgical site while limiting systemic exposure.
This study is a prospective, single-center, randomized, double-blind, placebo-controlled, parallel-group clinical trial. Seventy patients undergoing primary unilateral total knee arthroplasty for primary knee osteoarthritis will be randomly assigned in a 1:1 ratio to an experimental group or a placebo control group.
Before skin incision, participants in the experimental group will receive tranexamic acid by local intraosseous injection into the cancellous bone of the tibial plateau and the medial and lateral condyles of the distal femur. Participants in the control group will undergo the same procedure using an equal volume of normal saline. Surgical technique, perioperative analgesia, rehabilitation, and other routine perioperative management will be standardized between the two groups.
The primary outcome is total perioperative blood loss, assessed using perioperative hematologic measurements through postoperative day 3. Secondary outcomes include postoperative hemoglobin reduction, transfusion rate and volume, postoperative pain, knee swelling, range of motion, functional recovery, length of hospital stay, and safety outcomes such as symptomatic deep vein thrombosis, pulmonary embolism, wound complications, infection, and other adverse events. Functional recovery will be assessed during follow-up through 3 months after surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to this arm will receive a total dose of 2 g of tranexamic acid by local intraosseous injection before skin incision during primary unilateral total knee arthroplasty. Tranexamic acid 1 g will be administered into the cancellous bone of the tibial plateau, and the remaining 1 g will be administered into the medial and lateral condyles of the distal femur. All other surgical, analgesic, and rehabilitation procedures will follow the standardized perioperative protocol.
Drug: Tranexamic Acid
Participants assigned to this arm will undergo the same intraosseous injection procedure before skin incision during primary unilateral total knee arthroplasty but will receive an equal volume of normal saline instead of tranexamic acid. All other surgical, analgesic, and rehabilitation procedures will be identical to those in the experimental arm.
Drug: Normal Saline
A total dose of 2 g of tranexamic acid will be administered by local intraosseous injection before skin incision during primary unilateral total knee arthroplasty. Of the total dose, 1 g will be injected into the cancellous bone of the tibial plateau, and 1 g will be injected into the medial and lateral condyles of the distal femur. The intervention will be administered using a standardized intraosseous injection technique.
Normal saline will be administered by the same local intraosseous injection procedure before skin incision during primary unilateral total knee arthroplasty. The volume, injection sites, timing, and administration procedure will be matched to those used in the experimental group.
Total Perioperative Blood Loss
Total perioperative blood loss will be calculated in milliliters (mL) using perioperative hematologic measurements and estimated blood volume based on preoperative and postoperative laboratory values.
Time frame: From preoperative baseline through postoperative day 3
Maximum Decrease in Hemoglobin
Maximum decrease in hemoglobin from the preoperative value to the lowest postoperative value, expressed in g/L.
Time frame: From preoperative baseline through postoperative day 3
Allogeneic Red Blood Cell Transfusion Rate
Proportion of participants who receive at least one allogeneic red blood cell transfusion from the start of surgery through hospital discharge.
Time frame: From the start of surgery through hospital discharge,an anticipated average of 5-7 days.
Volume of Allogeneic Red Blood Cell Transfusion
Total volume of allogeneic red blood cells transfused from the start of surgery through hospital discharge.
Time frame: From the start of surgery through hospital discharge,an anticipated average of 5-7 days.
Pain Intensity at Rest
Postoperative pain at rest will be assessed using the Visual Analog Scale (VAS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores indicate greater pain intensity.
Time frame: Postoperative day 1, postoperative day 3
Pain Intensity During Activity
Postoperative pain during activity will be assessed using the Visual Analog Scale (VAS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores indicate greater pain intensity.
Time frame: Postoperative day 1, postoperative day 3
Knee Swelling
Knee circumference measured 10 cm above the superior border of the patella.
Time frame: Preoperative baseline, postoperative day 1, and postoperative day 3
Knee Range of Motion
Knee range of motion measured in degrees.
Time frame: Preoperative baseline, postoperative day 1, and postoperative day 3
Knee Functional Score
Knee function will be assessed using the Hospital for Special Surgery (HSS) Knee Score. The total score ranges from 0 to 100, with higher scores indicating better knee function.
Time frame: Within 24 hours before hospital discharge, 4 weeks after surgery, and 3 months after surgery
Length of Hospital Stay
Duration of postoperative hospitalization, expressed in days.
Time frame: From the day of surgery through hospital discharge, an anticipated average of 5-7 days.
Symptomatic Deep Vein Thrombosis
Incidence of symptomatic deep vein thrombosis confirmed by vascular ultrasonography.
Time frame: Up to 30 days after surgery
Symptomatic Pulmonary Embolism
Incidence of symptomatic pulmonary embolism confirmed by computed tomography pulmonary angiography when clinically indicated.
Time frame: Up to 30 days after surgery
Other Postoperative Complications
Incidence of postoperative complications, including wound infection, wound drainage or poor healing, neurovascular injury, systemic allergic reaction, and abnormal liver or kidney function.
Time frame: Up to 30 days after surgery
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Apr 2027, 6 months later.
Of 88 non-industry phase 4 interventional studies under Osteoarthritis, Knee, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 32. This study's planned 6 months is below that.
Counting every sponsor, half of 97 studies reached it within 19 months; a quarter within 10 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tranexamic Acid
The Second Affiliated Hospital of Kunming Medical University